Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01861340 · ClinicalTrials.gov registry record · Early Phase 1
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
A Early Phase 1 study of Myeloma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01861340 is a Early Phase 1 study of Myeloma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 20 participants, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01861340, a Early Phase 1 study of Myeloma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
Conditions Studied
Interventions
- DRUG Lenalidomide, Dexamethasone, and MEDI-551
Study Locations (1)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01861340
The ClinicalTrials.gov registry entry for NCT01861340 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 29 other Myeloma trials with a reported enrollment target (80% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide, Dexamethasone, and MEDI-551 is the first listed.
NCT01861340 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01861340 about?
NCT01861340 is a clinical study titled "Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma". This research study is being done to see if combining the investigational chemotherapy drug, MEDI-551 with the known anti-myeloma drugs, Lenalidomide and Dexamethasone will reduce your myeloma cancer stem cells.
What is the current status of trial NCT01861340?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2014-05. Estimated completion is 2016-07.
What conditions does trial NCT01861340 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT01861340?
The interventions under investigation include: Lenalidomide, Dexamethasone, and MEDI-551 (DRUG).
Who is sponsoring clinical trial NCT01861340?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01861340 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
ACTIVE NOT RECRUITING · Early Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 1
-
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
RECRUITING · Phase 2
-
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.